Alborz Medical University Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2017
NCT03193944
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Alborz Medical University | Alborz University of Medical Sciences | Assistant Professor of Alborz University of Medical Sciences

Active Ingredients

Drugs in Phase 3 Trials (1)

dexamethasone (1 trial)

Drugs in Phase 2 Trials (3)

autologous umbilical cord blood (1 trial)

umbilical cord mesenchymal stem cells (1 trial)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Palsy (Phase 2)

Lipid Metabolism Disorders (Phase 2)

Metabolic Diseases (Phase 2)

Metabolic Syndrome (Phase 2)

Muscle Spasticity (Phase 2)

Obesity, Abdominal (Phase 2)

Vitamin D Deficiency (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4